Cargando…

Evolution of Lung Cancer in the Context of Immunotherapy

Immunotherapy, as a novel treatment, has brought new hope to many patients with cancer, including patients with lung cancer. However, the overall cure rate and survival rate of lung cancer are still not satisfactory. The process of evolution has improved the ability of tumors to adapt to immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Sheng, Wang, Ruilin, Tang, Hong, Wang, Lili, Zhang, Zhe, Yang, Sen, Jiao, Shuyue, Wu, Xuan, Wang, Shuai, Wang, Mingyue, Xu, Cong, Wang, Qiming, Wu, Yufeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780173/ https://www.ncbi.nlm.nih.gov/pubmed/33447125 http://dx.doi.org/10.1177/1179554920979697

Ejemplares similares

Case report: sequential use of almonertinib based on the EGFR exon 20 insertion mutation achieves long-term control for advanced non-small cell lung cancer patients
por: Wang, Ruilin, et al.
Publicado: (2022)

Upregulation of IBSP Expression Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma
por: Wang, Mingyue, et al.
Publicado: (2019)

MICA enhances sensitivity to cisplatin in patients with extensive small cell lung cancer via downregulation of ABCG2
por: Wu, Yufeng, et al.
Publicado: (2020)

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer
por: Yu, Limeng, et al.
Publicado: (2023)

Riddle of the Sphinx: facts and evidence regarding the link between mental stress and tumor occurrence and development
por: Wang, Ruilin, et al.
Publicado: (2022)

Depression induces poor prognosis associates with the down-regulation brain derived neurotrophic factor of serum in advanced small cell lung cancer
por: Wu, Yufeng, et al.
Publicado: (2016)

Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma
por: Yang, Sen, et al.
Publicado: (2020)

Current status of and progress in the treatment of malignant pleural effusion of lung cancer
por: Zhao, Yuhua, et al.
Publicado: (2023)

The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer
por: Zhao, Yuhua, et al.
Publicado: (2023)

Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report
por: Ma, Shuxiang, et al.
Publicado: (2020)

Emerging therapies for small cell lung cancer
por: Yang, Sen, et al.
Publicado: (2019)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Reduction of AZGP1 predicts poor prognosis in esophageal squamous cell carcinoma patients in Northern China
por: Tang, Hong, et al.
Publicado: (2016)

MEK inhibitors for the treatment of non-small cell lung cancer
por: Han, Jing, et al.
Publicado: (2021)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

PET-CT evaluation of the curative effect of crizotinib on malignant myofibroblastoma with rare mutation of ALK R401: a case report and literature review
por: Yang, Li, et al.
Publicado: (2018)

EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors
por: Liu, Yang, et al.
Publicado: (2022)

Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
por: Wang, Shuyue, et al.
Publicado: (2021)

The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: a prospective two-stage, two-center study
por: Zhang, Cuicui, et al.
Publicado: (2021)

Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study
por: Huang, Zhangfeng, et al.
Publicado: (2021)

Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review
por: Tang, Hong, et al.
Publicado: (2018)

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
por: Wu, Xuan, et al.
Publicado: (2020)

Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy
por: Gao, Ran, et al.
Publicado: (2022)

Genetic Alteration and Their Significance on Clinical Events in Small Cell Lung Cancer
por: Jiao, Shuyue, et al.
Publicado: (2022)

Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients
por: Wang, Zhe, et al.
Publicado: (2021)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

Predictive significance of HMGCS2 for prognosis in resected Chinese esophageal squamous cell carcinoma patients
por: Tang, Hong, et al.
Publicado: (2017)

Bilingual Language Control Flexibly Adapts to Cultural Context
por: Liu, Cong, et al.
Publicado: (2021)

Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small‐cell lung cancer
por: Hao, Lidan, et al.
Publicado: (2023)

A Nano Drug Delivery System Based on Angelica sinensis Polysaccharide for Combination of Chemotherapy and Immunotherapy
por: Wang, Min-Zhe, et al.
Publicado: (2020)

Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer
por: Wu, Tong, et al.
Publicado: (2019)

The Rho GTPase Family Genes in Bivalvia Genomes: Sequence, Evolution and Expression Analysis
por: Li, Xue, et al.
Publicado: (2015)

The Resistance Mechanisms of Lung Cancer Immunotherapy
por: Wang, Fen, et al.
Publicado: (2020)

The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective
por: Liang, Shuai, et al.
Publicado: (2023)

Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review
por: Zhang, Zhe, et al.
Publicado: (2021)

Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial
por: He, Zhen, et al.
Publicado: (2021)

Emerging phagocytosis checkpoints in cancer immunotherapy
por: Liu, Yu’e, et al.
Publicado: (2023)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

School Engagement and Context: A Multilevel Analysis of Adolescents in 31 Provincial-Level Regions in China
por: Liu, Fangqing, et al.
Publicado: (2021)

Early palliative care of non-small cell lung cancer in the context of immunotherapy
por: Pieniążek, Małgorzata, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_65l95qm0kkiafvqtj2t7tvba0r